NCT06490159Recruiting
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 16 Jun 2024
- Start date
- 1 Oct 2018
- Primary completion date
- 18 Jun 2028
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06490159
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Oct 2018 to the primary completion date, 18 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with severe complications (angina pectoris, myocardial infarction, or arrhythmia) or uncontrollable diabetes mellitus, blood hypertension, or bleeding tendency.
- Patients with a history of serious allergic reactions or serious drug allergy.
- Patients with a clinically relevant mental disorder that prohibits response to questionnaires.
Other
- Patients with a life expectancy of shorter than 3 months
- Patients for whom the attending physician considered that enrollment in the study is inappropriate.
Who the study is looking for
- unresectable or recurrent Gastric cancer (GC) histologically confirmed to be primary adenocarcinoma of the stomach.
- age over 20 years.
- Eastern Cooperative Oncology Group performance status score of 0-2.
- written informed consent following full study information is provided to the patient.
- progression or intolerance for first-line chemotherapy comprising fluorinated pyrimidine and platinum anticancer drugs (cisplatin or oxaliplatin) for advanced GC.
- presence of evaluable lesions as confirmed using a computed tomography (CT) or magnetic resonance imaging.
Age in the registry: 20 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kawasaki Medical University Coordinator of this site? Confirm its status | Kurashiki | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.